Janssen-sponsored congress materials from select Neuroscience Conferences:

• ECNP (October 2-5, 2021)
• Psych Elevate (June 11-13, 2021)
• ASCP (June 1-4, 2021)
• ISPOR (May 17-20, 2021)
• APA 2021 (May 1-3, 2021)
• CPNP 2021 (April 19-23, 2021)
• AMCP 2021 (April 12-16, 2021)
• ACTRIMS 2021 (February 24-26, 2021)
• Psych Congress 2020 (September 10-13, 2020)
• MSVirtual 2020 (September 11-13, 2020)

 

Data presented at the 2021 European College of Neuropsychopharmacology Meeting

Virtual congress materials and abstracts from ECNP can be accessed directly at:https://www.ecnp.eu/Congress2021/ECNPcongress/programme/Programme

Abstract

• Paliperidone palmitate 6-month long-acting injectable for schizophrenia: A randomised, double-blind, multicenter, noninferiority phase 3 study.

 

Data presented at the 2021 Psych Elevate Annual Meeting

Please refer to the Psych Elevate website directly for oral presentations and posters available for registered attendees at: https://virtual.elevate.psychcongress.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster title

• Effect of Paliperidone Palmitate Versus Oral Antipsychotics on Treatment Failure in Black/African American and Young Adult Subpopulations: A Pooled Analysis of Data from the DREaM and PRIDE Studies

 

Data presented at the 2021 American Society of Clinical Psychopharmacology Annual Meeting

Please refer to the ASCP website directly for oral presentations and posters available for registered attendees at: https://ascp.societyconference.com/v2/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

• Long-Term Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study
• Intranasal Esketamine Effectively Treats Treatment-Resistant Depression in Adults Regardless of Baseline Irritability
• Evaluation of Treatment Failure in Real-World Management of Patients with Recent-Onset Schizophrenia from the Disease Recovery Evaluation and Modification (DREaM) Study
• Efficacy and Safety of Esketamine Nasal Spray by Sex in Patients with Treatment-Resistant Depression: Findings from Randomized, Controlled Trials (encore poster)
• Characteristics of Real-world Commercially Insured Patients Initiated on Esketamine Nasal Spray, or Other Major Depressive Disorder Therapies in the United States (oral presentation)

 

Data presented at the 2021 Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Meeting

Abstracts and select podium presentations & posters from ISPOR conferences can be accessed directly at https://www.ispor.org/heor-resources/presentations-database/search

Abstracts

• Characteristics of Real-world Commercially Insured Patients with Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies
• Economic Burden of Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the United States
• Universal Screening for Suicidal Thoughts and Behaviors in a Large Healthcare System’s Hospital and Emergency Departments (encore)
• Association Between Social Determinants of Health and Depression Among Patients with Psoriasis in the United States
• Patient Profiles and Hospital Re-encounters of Patients with a Hospital Emergency Department Visit or Inpatient Admission for Major Depressive Disorder (oral presentation)
• Healthcare Resource Utilization and Costs Before and After Long-Acting Injectable Antipsychotic (LAI) Use in Commercially Insured Young Adults with Schizophrenia (encore)
• Projecting the Economic Outcomes of Switching Patients with Schizophrenia from Oral Atypical Antipsychotics to Once-Monthly Paliperidone Palmitate and Once-Every-Three-Months Paliperidone Palmitate Assessment of Patient Out-of-Pocket Costs for Antipsychotic Treatments Among Medicaid Beneficiaries with Schizophrenia
• Early Impact of COVID-19 Pandemic on Antipsychotic Medication Use Among Patients with Schizophrenia

 

Data presented at the 2021 American Psychiatric Association Annual Meeting

Please refer to the APA website directly for oral presentations and posters available for registered attendees at: https://apa.onlineeventpro.freeman.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

• Response to Esketamine Nasal Spray in Patients With Major Depressive Disorder and Acute Suicidal Ideation/Behavior Without Evidence of Early Response
• Efficacy and Safety of Esketamine Nasal Spray by Sex in Patients With Treatment-Resistant Depression: Findings From Randomized, Controlled Trials
• Characteristics of United States (US) Veterans With Major Depressive Disorder and Their Current Standard of Care: A Real-Word Data Analysis
• Universal Acute Care Suicide Screening Among the General Population and Individuals With Major Depressive Disorder in a Large Healthcare System
• Assessing Expert Consensus Around Progression and Mitigation of Cognitive Decline Following Onset of Schizophrenia Disease: A Delphi Method Study
• Systematic Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Use of Long-Acting Injectable Antipsychotics in the United States
• A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Acute and Maintenance Antipsychotic Treatment
• Healthcare Resource Utilization and Costs Pre-/Post-Long-Acting Injectable Antipsychotic Use in Commercially Insured Young Adults With Schizophrenia
• Reductions in Behavioral Healthcare Service Use Among Patients With Schizophrenia Associated With the Covid-19 Pandemic

 

Data presented at the 2021 College of Psychiatric and Neurologic Pharmacists Annual Meeting

Please refer to the CPNP website directly for oral presentations and posters available for registered attendees at: https://cpnp.org/ed/meeting/2021 or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Abstracts

• Efficacy of Esketamine in Conjunction with Adjunctive Atypical Antipsychotics in Patients with Major Depressive Disorder and Active Suicidal Ideation with Intent
• Societal Burden Associated With Schizophrenia Relapse Among US Veterans
• Understanding the Impact of COVID-19 on Schizophrenia Population Health Management: A Mixed-Methods Study of Population Health Decision Makers

 

Data presented at the 2021 Academy of Managed Care Pharmacy Annual Meeting

Virtual congress materials from the AMCP Annual Meeting can be accessed directly at https://amcpannual2021.pathable.co/

Abstracts

• Healthcare resource use and costs associated with persistence on early versus late lines of therapy in patients with treatment-resistant depression
• Understanding schizophrenia population health management: a mixed-methods study with U.S. population health decision makers
• Relationship between the short-form 12 (SF-12) and schizophrenia symptom rating scales in a randomized controlled clinical trial of paliperidone palmitate 3 monthly formulation

 

Data presented at ACTRIMS 2021

Virtual congress materials from ACTRIMS congress can be accessed directly at https://www.abstractsonline.com/pp8/#!/9245.

Abstracts

• Assessing the Impact of Disease Activity and Fatigue Symptom on Work Productivity and Activity Impairment in Patients with Relapsing Multiple Sclerosis
• Changes in Fatigue Status on the FSIQ-RMS Symptoms Domain in the Phase 3 OPTIMUM Study
• Evaluating the Impact of Fatigue Symptoms on Work Productivity and Activity Impairment using Longitudinal Data from the Phase III OPTIMUM study
• MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity
• Measuring the symptoms and impacts of fatigue in adults with relapsing multiple sclerosis using a novel disease specific scale: A real-world study in US population
• The Humanistic Burden Associated with Fatigue in Relapsing-remitting Multiple Sclerosis.
• The Economic Burden Associated with Fatigue in Relapsing-remitting Multiple Sclerosis
• A Central Effect of Ponesimod on Neuroinflammation in a Pre-Clinical Model of Multiple Sclerosis
• Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence

 

Data presented at Psych Congress 2020

Virtual congress materials from Psych Congress can be accessed directly at https://www.psychcongress.com/posters.

Posters:

• Evaluation of Treatment Failure in a 20-month Randomized, Open-Label Study of Paliperidone Palmitate Versus Oral Antipsychotics in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder
• Evaluation of Major Treatment Failures from the Disease Recovery Evaluation and Modification (DREaM) Study
• A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Antipsychotic Medications
• Hospitalizations, Emergency Room Visits and Adherence Among Patients With Schizophrenia Initiated on Long-Acting Injectable Versus Oral Antipsychotics: A Systematic Review and Meta-Analysis
• Medication Adherence, Healthcare Resource Utilization, and Costs among Medicaid Beneficiaries with Schizophrenia Treated with Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate
• Drivers of Prescribing Long-Acting Injectable Antipsychotics to Patients with Schizophrenia
• Characteristics of young adults with schizophrenia using Colorado’s All Payer Claims Database (CO-APCD)
• Real world analysis of insurance churn among young adult patients with schizophrenia using the Colorado All Payer Claims Database (CO-APCD)
• The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System
• Antipsychotic Treatment Utilization and Healthcare Spending in Medicaid Beneficiaries by States and Regions Within the United States
• Non-Healthcare Societal Burden of Schizophrenia Among Veterans
• Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting
• Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression
• Budget impact analysis of Esketamine Nasal Spray in a sub-population of adults with major depressive disorder and high unmet need: payer perspective in the United States
• Cluster Analysis of Care Pathways in Major Depressive Disorder with Suicidal Ideation or Probable Suicide Attempt
• Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder Having Active Suicidal Ideation with Intent: Pooled Randomized, Controlled Trials

 

Data presented at MSVirtual 2020

Virtual congress materials from MSVirtual congress can be accessed directly at https://library.msvirtual2020.org/virtual-library-search?product_id=7.

Posters

• Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study – P0071
• Effect on disability measures and MSFC in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study – P0204
• Cardiac Safety of Ponesimod in Relapsing Multiple Sclerosis in the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study -P0194
• Establishing Meaningful Change Threshold in Multiple Sclerosis related Fatigue on Fatigue Symptoms & Impacts Questionnaire-Relapsing MS (FSIQ-RMS) – P1027
• Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis – P0215
• Treatment Persistency for Patients in a Phase 2 Long-Term Extension Study of Ponesimod – P0177
• Pharmacokinetic-Pharmacodynamic Models of Lymphocyte Count and Heart Rate Following Ponesimod Dosing in a Phase 2 Study in Multiple Sclerosis Patients – P0224
• A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale – P1004
• Comorbidity and Economic Burdens of Fatigue Among Patients with Relapsing-Remitting Multiple Sclerosis in the United States – P0857
• Treatment Preferences of Patients with Relapsing Multiple Sclerosis: A Discrete Choice Experiment – P1064
• Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annual Relapse Rate – P0049
• Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Longitudinal Model-Based Meta-Analysis for Confirmed Disability Accumulation – P0048
• Quality of life and economic burden of fatigue in people with multiple sclerosis: a systematic literature review – P1048